Clinical Trial Update: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) [Phase 3]

View source ↗

Summary

Phase 3 trial results for empagliflozin in heart failure with reduced ejection fraction have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2021-05-18